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Abstract 
Background: Production of recombinant drugs in process‑friendly endotoxin‑free bacterial factories targets to a 
lessened complexity of the purification process combined with minimized biological hazards during product applica‑
tion. The development of nanostructured recombinant materials in innovative nanomedical activities expands such 
a need beyond plain functional polypeptides to complex protein assemblies. While Escherichia coli has been recently 
modified for the production of endotoxin‑free proteins, no data has been so far recorded regarding how the system 
performs in the fabrication of smart nanostructured materials.
Results: We have here explored the nanoarchitecture and in vitro and in vivo functionalities of CXCR4‑targeted, self‑
assembling protein nanoparticles intended for intracellular delivery of drugs and imaging agents in colorectal cancer. 
Interestingly, endotoxin‑free materials exhibit a distinguishable architecture and altered size and target cell penetra‑
bility than counterparts produced in conventional E. coli strains. These variant nanoparticles show an eventual proper 
biodistribution and highly specific and exclusive accumulation in tumor upon administration in colorectal cancer 
mice models, indicating a convenient display and function of the tumor homing peptides and high particle stability 
under physiological conditions.
Discussion: The observations made here support the emerging endotoxin‑free E. coli system as a robust protein 
material producer but are also indicative of a particular conformational status and organization of either building 
blocks or oligomers. This appears to be promoted by multifactorial stress‑inducing conditions upon engineering of 
the E. coli cell envelope, which impacts on the protein quality control of the cell factory.
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coli, Endotoxin‑free strains
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Background
The physiological diversity of microorganisms makes 
them suitable platforms for the cost-effective fabrication 
of a diversity of substances and macromolecules, includ-
ing emerging nanostructured materials such as metal 
deposits, polymeric granules, functional amyloids and 
viruses or virus-like protein assemblies [1]. Being highly 
versatile, environmentally friendly and fully scalable, 
microbial fabrication is in many aspects more convenient 
than chemical synthesis [2–4]. Microbial cells, namely 
bacteria and yeast, have been exploited as factories for 
the production of many protein drugs that have been 
approved for use in humans. Historically, Escherichia 
coli was the pioneering cell factory for protein produc-
tion because of the well-known genetics and metabolism. 
However, the presence of endotoxins in the cell envelope 
of Gram-negative bacteria poses an up to now unsolvable 
obstacle in the use of this organism for drug production 
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[5]. Lipopolysaccharide (LPS) removal increases the 
complexity of protein purification processes, and it is 
recognized that LPS, even in low amounts, is a common 
contaminant of complex protein complexes such as bac-
teriophages [6] and also of plain recombinant proteins 
[7]. In fact, contaminant LPS and other cell envelope 
components are responsible for wrongly attributed bio-
logical effects of recombinant proteins tested in biomedi-
cal assays, and for poor biocompatibility (some examples 
can be found in [8–10]). In this context, Gram-positive 
bacteria, yeast and mammalian cells are endotoxin-free 
alternatives to E. coli, and their prevalence in protein 
drug production has steadily increased [11, 12], although 
not absent of problems.
Very recently [13], endotoxin-free E. coli strains have 
been developed by fine multi-step mutagenesis as a way 
to merge the versatility of E. coli as an advantageous pro-
tein production platform in the absence of endotoxic 
contaminants in its products. Those strains have been 
proved efficient in the production of diverse soluble pro-
tein species [13] and also of inclusion bodies intended as 
smart topologies [14] or as functional amyloids for intra-
cellular protein release [15]. We wanted here to explore 
how the production, functionalities and nanoarchitecture 
of a complex, virus-like protein nanoparticle (T22-GFP-
H6) designed as drug carrier [16] would be affected by 
the use of this particular fabrication platform. These par-
ticles are formed by a self-organizing, CXCR4-targeted 
polypeptide that accumulates, in the assembled form, 
in tumoral tissues of colorectal cancer animal mod-
els [16, 17]. Accumulation in tumor is promoted by the 
N-terminal peptide T22, which is a potent ligand of the 
cell surface cytokine receptor CXCR4 [16]. CXCR4 is 
overexpressed in colorectal cancer cells and linked to 
tumor aggressiveness [18]. The combination of the highly 
cationic T22 peptide with the C-terminal histidine tail 
in a modular protein promotes the self-assembly of the 
whole construct, favored by the bipolar charge distribu-
tion of the building block surface [19]. Recently, we have 
observed that strain-dependent genetic features of the 
producing bacteria impact on tumor targeting and on 
the whole-body biodistribution of the oligomeric con-
struct upon its systemic administration [20]. Then, we 
were interested in dissecting the structure and activities 
of these tumor-homing nanoparticles when produced in 
endotoxin-free E. coli cells, whose complex genetic devel-
opment might have resulted in relevant physiological 
shifts.
Methods
Strains, plasmids and media
T22-GFP-H6 is a tumor-targeted modular protein that 
self-assembles as toroid nanoparticles of about 12 nm of 
diameter. These oligomers are fully stable in  vivo upon 
tail vein administration in colorectal cancer mice mod-
els [17] and accumulate intracellularly in primary tumor 
and in metastatic foci [16]. T22-GFP-H6 protein nano-
particles were produced in the KPM22 L11-derivative 
[21], endotoxin-free strain KPM335 (msbA52, ΔgutQ, 
ΔkdsD, ΔlpxL, ΔlpxM, ΔpagP, ΔlpxP, ΔeptA, frr181) 
and its parental K-12 strain BW30270 (CGSC#7925–
MG1655; F−, rph+, fnr+) with a wild-type LPS. The 
design of KPM335, based on the incorporation of non-
reverting deletions of seven genes to disrupt Kdo biosyn-
thesis and modifications of lipid IVA, prevents the strain 
from regaining the potential to synthesize normal LPS or 
endotoxically active lipid IVA derivatives through acquir-
ing mutations. Also, E. coli K-12 MC4100 ([araD139], 
(argF-lac)169, λ—relA1, rpsL150, rbsR22, flb5301, deoC1, 
pstF25 StrepR) and BL21 Origami B [F− ompT hsdSB(rB− 
mB−) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB (KanR, 
TetR)] (Novagen, Darmstadt, Germany) were used for 
protein production as controls. KPM335, BW30270 
and MC4100 were transformed with plasmid pTrc99a, 
whereas Origami B was transformed with a pET22b-
derived plasmid. All expression plasmids contained the 
T22-GFP-H6 DNA sequence optimized by the codon 
usage of E. coli and have been described previously [20]. 
Bacteria were always grown in Lysogeny Broth (LB) rich 
media [22]. Part of the protein was produced with the 
assistance of the Protein Production Platform of CIBER-
BBN/IBB, at the UAB (http://www.nanbiosis.es/unit/
u1-protein-production-platform-ppp/).
Competent cells and transformation
Cultures were grown overnight at 37  °C with shaking at 
250  rpm and used as a 1/100 inoculum in 50  ml of LB. 
After reaching an optical density (OD550) between 0.2 
and 0.4, MC4100, BW30270 and Origami B cultures were 
centrifuged (4000×g) at 4  °C for 15  min. Pellets were 
resuspended in 12.5 ml of cold and sterile 50 mM CaCl2 
and incubated for 45 min in an ice bath. Cells were cen-
trifuged again as described above and resuspended in 
1.25 ml of cold and sterile 50 mM CaCl2 in glycerol (15 % 
v/v) to prepare aliquots of 200 µl and stored at −80 °C. To 
transform the cells, 40 ng of plasmid DNA were added to 
the competent cells. The mixtures were incubated on ice 
for 30–60 min, warmed up to 42  °C for 45 s and placed 
on ice for 30 s. After incubation, 800 µl of LB media were 
added, and transformed cells were incubated at 37  °C 
for 1  h. Finally, the cells were plated on LB-agar plates 
containing the corresponding antibiotic. In the case of 
KMP335 strain, cells were grown to an OD550 between 
0.2 and 0.4, placed on ice for 20 min and sedimented by 
centrifugation (3100×g, 4  °C, 20  min). The pellets were 
centrifuged and resuspended successively in 40, 20 and 
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10  ml of H2O (ice-cold and sterile), followed by a wash 
with 5 ml of 10 % glycerol (ice-cold and sterile). The final 
pellet was resuspended in 1  ml of 10  % glycerol (ice-
cold and sterile) to prepare 50-µl aliquots for storage at 
−80  °C. Electrocompetent KPM335 cells were trans-
formed by electroporation in pre-chilled 0.2  cm elec-
troporation cuvettes using 50  µl of competent cells and 
40 ng of plasmid DNA. Cells were pulsed using a Gene 
Pulser MX cell electroporator (Bio-Rad, Hercules, CA, 
USA) at 25 µF, 200 Ω, 2500 V and 4.7–4.8 ms. Immedi-
ately after the pulse, 800  µl of LB medium were added, 
and the mixture was incubated at 37 °C for 1 h. Cells were 
plated on LB-agar plates containing ampicillin (100  µg/
ml) and incubated at 37 °C overnight.
Protein production and purification
Overnight cultures were inoculated in 500  ml of LB 
media with 100  µg/ml ampicillin in 2-L flasks. Strepto-
mycin (at 30 µg/ml) was also added to MC4100 cultures, 
and tetracycline (100  µg/ml) and kanamycin (33  µg/ml) 
to Origami B cultures. Each culture was grown at 37  °C 
and 250 rpm to an OD550 of about 0.5 before isopropyl-
β-d-thiogalactoside (IPTG) was added to 1 mM to induce 
recombinant gene expression. T22-GFP-H6 was pro-
duced overnight at 20  °C with shaking (250  rpm) in all 
cases.
After overnight production, cultures were centrifuged 
(3280×g, 4  °C, 40  min), and the cell pellets were resus-
pended in 20 mM Tris–HCl, pH 8.0, containing 500 mM 
NaCl, 20  mM imidazole (buffer A), and an EDTA-free 
protease inhibitor cocktail (Complete EDTA-free, Roche 
Diagnostics, Indianapolis, IN, USA). Intra-cellular pro-
tein was extracted by cell disruption using a French press 
(Thermo FA-078A) at 1100 psi, and purified by His-tag 
affinity chromatography using a 1-ml HiTrap Chelating 
HP column (GE Healthcare, Piscataway, NJ, USA) in an 
ÄKTA purifier FPLC (GE Healthcare). Protein separa-
tion was achieved with a linear imidazole gradient from 
20  mM to 500  mM, by diluting 20  mM Tris–HCl, pH 
8.0, plus 500  mM NaCl and 500  mM imidazole (buffer 
B) in buffer A, and fractions were collected and dialyzed 
against 166 mM NaHCO3, pH 7.4. The amount of protein 
was determined by Bradford’s assay [23], and the integ-
rity of the protein was analyzed by sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), fol-
lowed by Western blot analysis as described below.
Western blot analysis
Separated fractions were subjected to 10  % SDS-PAGE 
according to Laemmli’s method [24]. Protein was trans-
ferred to nitrocellulose membranes (GE Healthcare, 
Piscataway, NJ, USA) that were blocked overnight with 
5 % skim milk in PBS. After blocking, membranes were 
incubated with anti-GFP antibody (1:500, sc-8334, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), followed by 
incubation with a secondary HRP-conjugated anti-rab-
bit IgG (H + L) antibody (Bio-Rad, Hercules, CA, USA) 
at a dilution of 1:2000. Protein bands were visualized 
with a solution of 25  % cold methanol, 0.2  % H2O2 and 
0.65  mg/ml of 4-chloronaftol in PBS, and images were 
obtained using a GS800 Calibrated Densitometer scanner 
(Bio-Rad).
Fluorescence intensity
Fluorescence intensity of T22-GFP-H6 was determined 
in a Varian Cary Eclipse fluorescence spectrometer (Agi-
lent Technologies, Mulgrave, Australia) at excitation and 
emission wavelengths of 450 and 510 nm, respectively.
Particle size and zeta potential
Size distribution and zeta potential of nanoparticles were 
measured by dynamic light scattering (DLS) at 633  nm 
(Zetasizer Nano ZS, Malvern Instruments Limited, Mal-
vern, Worcestershire, UK). Samples were analyzed by 
triplicate averaging of fifteen single measurements.
Mass spectrometry (MS) analysis
Purified protein was diluted 1:2 with H2O MilliQ and 
dialyzed against 50  mM of NH4HCO3 for 1.5  h. After 
dialysis, protein was mixed with a matrix of 2.6 dihy-
droxyacetophenone (1:1), and 1  µl of the mixture was 
deposited on a ground steel plate. Samples were analyzed 
using a lineal method in an UltrafleXtreme MALDI-TOF 
instrument (Bruker Daltonics, Bremen, Germany) with 
ion acceleration of 25 kV.
Circular dichroism (CD)
CD measurements were carried out in a Jasco J-715 spec-
tropolarimeter at 25  °C and 10  µM protein in 160  mM 
NaHCO3, pH 7.4. CD and high-tension (HT) voltage 
spectra were obtained over a wavelength range of 200–
250 nm at a scan rate of 50 nm/min, a response time of 
0.5 s, and a bandwidth of 0.5 nm.
Electron microscopy
To visualize the ultrastructure of protein nanoparticles 
by transmission electron microscopy (TEM), 2 µl of puri-
fied protein (0.2  mg/ml) were placed on carbon-coated 
copper grids for 1  min. Excess of sample was bloated 
and 2 µl of 1 % w/v uranyl acetate were added for nega-
tive staining. Samples were immediately visualized in a 
TEM Jeol JEM-1400 (Jeol Ltd., Tokyo, Japan) equipped 
with a Gatan CCD Erlangshen ES1000 W camera (Gatan 
Inc, Abingdon, UK) and operating at 80  kV. Ultrastruc-
tural analyses of nanoparticle morphology were com-
plemented with imaging in a nearly native state with a 
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Field Emission Scanning Electron Microscope (FESEM). 
For that, protein samples were directly deposited over 
silicon wafers (Ted Pella, Reading, CA, USA), air dried 
and observed with a high resolution in-lens secondary 
electron detector through a FESEM Zeiss Merlin (Zeiss, 
Oberkochen, Germany), operating at 2 kV.
Analysis of cell internalization
HeLa cells were cultured at 37 °C in a humidified atmos-
phere with 5 % CO2 for 24 h and plated in treated 24 well 
plates (Nunclon surface, Nunc 150628) with MEM-α 
medium supplemented with 10 % fetal bovine serum (FBS) 
and 2 mM Glutamax (Gibco, Rockville, MD, USA). Later, 
medium was removed and the cells were washed with Dul-
becco’s phosphate-buffered saline (DPBS). Then, 25  nM 
of T22-GFP-H6 in 250  µl Optipro supplemented with 
2  mM  l-glutamine was added. After incubation at 37  °C 
for 1 h, cells were treated with trypsin in DPBS (1 mg/ml) 
for 15  min, centrifuged at 300×g for 15  min, and pellets 
were resuspended in 300 µl DPBS. Samples were analyzed 
by flow cytometry using a FACSCanto system (Becton–
Dickinson, Franklin Lakes, NJ, USA) with a 15  W air-
cooled argon-ion laser at 488 nm excitation for GFP.
Confocal microscopy
HeLa cells were plated on a MatTek culture dish (Mat-
Tek Corporation, Ashland, MA, USA) at 150,000 cells/
plate and incubated at 37  °C for 24 h. After incubation, 
medium was removed to wash the cells twice with DPBS. 
Optipro medium supplemented with 2 mM l-glutamine 
and 25  nM T22-GFP-H6 were added, and cells were 
incubated at 37  °C for 1  h. To visualize the samples, 
plasma membranes and the nucleus were labeled using 
2.5  mg/ml CellMask Deep Red and 0.2  mg/ml Hoechst 
33342 (Molecular Probes, Eugene, OR, USA), respec-
tively. A confocal laser scanning microscope TCS-SP5 
(Leica Microsystems, Heidelberg, Germany) was used 
to analyze the samples, and the images were processed 
through the Imaris Bitplane software (Bitplane, Zurich, 
Switzerland).
Determination of in vivo biodistribution
This study was approved by the Institutional Animal Eth-
ics Committee. We implanted CXCR4-overexpressing 
SP5 human colorectal tumor line to generate subcuta-
neous colorectal tumors in swiss nude mice (Charles 
River, France) as previously described [16, 17]. When 
tumors reached ca. 500 mm3, mice were randomly allo-
cated to Origami B, MC4100, KPM335, BW30270 or 
buffer-treated groups (N = 3–5/group). The experimen-
tal mice received a single intravenous bolus of the cor-
responding nanoparticle (500  μg in carbonate buffer, 
pH 7.4), whereas control mice received only buffer. Five 
hours after the administration, we measured ex vivo the 
fluorescence emitted by the nanoparticles accumulated 
in the whole and slice sectioned tumor and normal tis-
sues (kidney, lung, and heart, liver and brain) using IVIS® 
Spectrum equipment (Perkin Elmer, Waltham, MA, 
USA). The fluorescence signal was digitalized, and after 
subtracting the autofluorescence, it was displayed as a 
pseudocolor overlay and expressed as Radiant efficiency. 
Data were corrected by the specific fluorescence emitted 
by the different nanoparticles. Signal difference between 
groups was determined by applying the non-parametric 
Mann–Whitney test.
Histological and immunohistochemical evaluation
At necropsy, tumors were fixed with 4 % formaldehyde in 
PBS for 24 h and embedded in paraffin for histological and 
immunohistochemical evaluation. 4  µm sections, were 
processed as previously described [16, 17] and haema-
toxylin and eosin (H&E) stained for histological analysis, 
that was performed by two independent observers. We 
assessed CXCR4 membrane expression and nanoparticle 
cell internalization in tumor and normal tissues by IHC 
using primary anti-CXCR4 (1:300; Abcam, Cambridge, 
UK) or anti-GFP (1:100; Santa Cruz Biotechnology, CA, 
USA), and secondary HRP conjugated antibody, followed 
by chromogenic detection. We quantified the percent-
age of CXCR4-expressing cells in relation to the total cell 
number and their staining intensity, scoring each sample 
from 0 to 3 (where 3 is the maximal intensity) and multi-
plying both parameters to obtain its H-score. Representa-
tive pictures were taken using CellэB software (Olympus 
Soft Imaging v3.3, Tokyo, Japan) at 400×.
Quantitative real‑time PCR
For isolation of total RNA, triplicate cultures of E. coli 
strains BW30270 and KPM335 were grown aerobically 
with shaking (250  rpm) at 37  °C in LB medium to the 
mid-exponential growth phase at an OD600 of 0.6–0.7. 
The bacterial cells were harvested in the presence of 
RNAprotect Bacteria Reagent for immediate RNA stabi-
lization prior to RNA isolation using the RNeasy Mini Kit 
and on-column DNase treatment in accordance with the 
recommendations of the manufacturer (Qiagen). RNA 
concentrations were determined using a NanoDrop 2000 
spectrophotometer (Thermo Scientific), and the integ-
rity of the RNAs was verified with RNA Nano Chips in 
an Agilent 2100 Bioanalyzer. The Maxima First Strand 
cDNA Synthesis Kit was used to generate cDNA from 
0.3  µg RNA following the manufacturer´s instructions 
(Thermo Scientific, Waltham, MA, USA). The cDNA lev-
els of chaperone genes were then analyzed by quantita-
tive real-time PCR (RT-qPCR) using a LightCycler 480 
Instrument II with LightCycler 480 SYBR Green I Master 
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reaction mixes according to the instructions of the manu-
facturer (Roche Diagnostics). RT-qPCR was performed 
with an initial denaturation at 95 °C for 5 min, followed 
by 45 cycles of 10  s at 95  °C, 10  s at 60  °C, and 10  s at 
72 °C. Each sample was analyzed in duplicate using 1:15 
and 1:50 dilutions of the cDNAs and the gene-specific 
primers listed in Table 1. The primer pairs (Table 1) were 
designed following the rules of highest possible sensi-
tivity and efficiency with the Primer3 2.3.4 plugin of the 
Geneious v9.0.5 software (Biomatters, Auckland, New 
Zealand). Relative expression levels of the target genes 
were normalized to the internal reference gene ihfB for 
the β-subunit of the integration host factor using the 
comparative 2−∆∆Ct method [25].
Results and discussion
The self-assembling protein T22-GFP-H6 (Fig.  1a) was 
produced in the endotoxin-free strain KPM335 and its 
parental BW30270, as well as in MC4100 and Origami 
B strains, used in previous studies for the routine fab-
rication of T22-GFP-H6 nanoparticles. While the gen-
eration time of KPM335 has increased by about 50 % in 
comparison to the parental wild-type strain, no signs of 
instability, lysis, foaming or cell death could be observed. 
In all cases, T22-GFP-H6 appeared as a stable full-length 
product showing the expected molecular mass of about 
30 kDa (Fig. 1b). The steadily observed double band was 
probably due to different conformational species of the 
protein. When purified by His affinity chromatography 
from bacterial cell extracts, T22-GFP-H6 was eluted 
in two separated peaks (P1 and P2) irrespective of the 
strain used for production (Fig.  1c). P2 has been previ-
ously observed as the one containing protein materials 
more efficient in cell penetration assays [20]. MS of these 
P2 samples revealed the expected molecular masses of all 
protein variants with minor signs of proteolytic instabil-
ity (more prevalent in MC4100 through the occurrence 
of a degradation fragment of 28.4 kDa; Fig. 1d), also con-
firming that the double band observed in blots (Fig. 1b) 
was indeed due to conformational variability instead to 
significant occurrence of truncated forms. Both protein 
yield and emitted fluorescence were significantly lower 
in KPM335 than in other strains (Fig. 2a), as well as the 
specific fluorescence emission of T22-GFP-H6 (Fig. 2b). 
While a moderate protein yield in recombinant KPM335 
was not unexpected according to previous reports refer-
ring to different produced protein species [13], a specific 
fluorescence emission lower than that observed in its 
parental BW30270 (and in other reference strains) was 
indicative of a differential conformation of T22-GFP-H6 
monomers or an alternate configuration of the resulting 
nanoparticles.
The formation of nanoparticles was firstly confirmed 
by DLS, revealing a regular size of the material rang-
ing between 10 and 15  nm, depending on the cell fac-
tory (Fig.  3a). Interestingly, and according to the above 
hypothesis of a particular organization of T22-GFP-H6 
as produced in KPM335, P1 nanoparticles produced 
in this strain were particularly large, reaching around 
75 nm in diameter (Fig. 3a). This variability did not result 
in appreciable modifications in the superficial charge of 
protein nanoparticles (Fig.  3b). The observed deviations 
in the size of protein materials were fully confirmed by 
TEM and FESEM morphometric analyses (Fig. 4).
When analyzing penetrability into CXCR4+ HeLa cells 
in culture, a convenient in vitro model for T22-empow-
ered nanoparticles [16], P2 materials resulted generically 
more efficient than P1’s (Fig. 5a). The exception found in 
Origami B cells is in agreement with previous observa-
tions [20], and it might be related to the less reducing 
cytoplasm in this bacterial strain and caused by a bot-
tom-up impact of protein conformation on microscopic 
functioning of the particles in cell interfaces, associated 
to favored di-sulfide bridge formation in this factory. Cell 
penetrability of P2 particles was comparatively screened 
again by confocal microscopy and the enhanced perfor-
mance of those produced in KPM335 fully confirmed 
Table 1 Primers used for RT-qPCR
a  Used for normalization of gene expression
Gene Primer Sequence Amplicon 
length 
(bp)
tig ECtig353F AGGGTCTGGAAGCGATCGAAG 301
ECtig653R GGGAAGGTCACGTCGATGGT
ibpA ECibpA85F CAGAGTAATGGCGGCTACCCT 299
ECibpA383R GCTTCCGGAATCACGCGTTC
hscB EChscB191F CGTTAATGCGCGCGGAATATTTG 301
EChscB491R AGTTGTTCGGCACTGCTTCG
hchA EChchA398F TCGCGGATGTTGTTGCCAG 300
EChchA697R CGCCGAAGTACCAGGTGAGA
grpE ECgrpE278F ACGAATTGCTGCCGGTGATTG 301
ECgrpE578R GCTACAGTAACCATCGCCGC
groL ECgroL583F TTCGACCGTGGCTACCTGTC 301
ECgroL883R GGGTTGCGATATCCTGCAGC
dnaK ECdnaK504F CATCAACGAACCGACCGCAG 300
ECdnaK803R TTTTCTGCCGCTTCTTTCAGGC
clpB ECclpB426F AATGCGTGGAGGTGAAAGCG 300
ECclpB725R ATATCCAGCGCCAGTACCCG
clpA ECclpA287F AGTCCTCCGGTCGCAATGAG 300
ECclpA586R CCAGCTCCTTCTCACGACCA
cbpA ECcbpA477F GCTGAATGTGAAGATCCCGGC 300
ECcbpA776R ACCAGACCTTTGCCTTTAACGC
ihfBa ECihfB9F GTCAGAATTGATAGAAAGACTTGCCACC 258
ECihfB266R CGATCGCGCAGTTCTTTACCAG
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(Fig.  5b). These nanoparticles accumulated intracellu-
larly in the perinuclear region, showing moderate nuclear 
penetrability (Fig. 5c).
The performance of P2 nanoparticles, those showing 
higher cell penetrability in  vitro, was evaluated in  vivo 
through analyzing their biodistribution and accumula-
tion in CXCR4-overexpressing tumor tissues, in a sub-
cutaneous mouse model of colorectal cancer. Upon 
systemic administration, all protein variants targeted 
and accumulated in the primary tumor, albeit to dif-
ferent extents (Fig.  6a–c), with materials produced in 
MC4100 being the most efficient. Nanoparticles pro-
duced in KPM335 showed results similar in efficacy to 
those manufactured in Origami B, the paradigmatic cell 
factory for T22-GFP-H6 [17], and slightly better than 
the parental BW30270 (although differences were not 
significant). In any case, the higher cell penetrability of 
these nanoparticles determined in cultured cell (Fig. 5a) 
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Fig. 3 Physical properties of protein nanoparticles. a Size of the self‑assembled nanoparticles purified in two elution peaks and measured by DLS. b 
Surface charge distribution of self‑assembled nanoparticles measured as zeta potential. Symbols mean significant differences: **p < 0.001; *p < 0.05
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Fig. 4 Morphometric characterization of nanoparticles ultrastructure. Representative TEM and FESEM (insets) images of all strains and main elution 
peaks 1 and 2. Scale bars represent 50 nm
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was not reflected by an enhanced tumor targeting 
in  vivo. As expected, accumulation of protein nanopar-
ticles was coincident with the overexpression of CXCR4 
in target tissues (Fig.  6d, e), and none of the protein 
materials was observed to accumulate in the evaluated 
normal non-target organs (namely kidney, lung, heart, 
liver, spleen and pancreas; Fig.  7a, b). The absence of a 
signal in kidney was indicative of a high stability in vivo 
of the nanoparticles that keep assembled in oligomers of 
size over the cut-off of renal clearance (~8 nm).
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Fig. 5 Cell penetrability of nanoparticles. a Internalization of self‑assembling nanoparticles analyzed by intracellular fluorescence of HeLa cells incu‑
bated with 25 nM of T22‑GFP‑H6 for 1 h. Internalize fluorescence (determined by flow cytometry) is corrected by specific fluorescence (determined 
by fluorimetry). The quotient represents relative protein amounts. b Internalization of nanoparticles visualized by confocal microscopy. Nucleus 
(blue) of HeLa cells were labeled using Hoechst 33342, membranes (red) were labeled with CellMask Deep Red. Cells were incubated with 25 nM of 
T22‑GFP‑H6 (green) for 1 h. Bars indicate 15 µm. c Three dimensional 3D reconstruction of T22‑GFP‑H6 nanoparticles (P2) from KPM335 into HeLa 
cells. Images were obtained using 35 layers per image. Three different fields of confocal microscopy as well as three angles were viewed through 
Imaris Bitplane Software. Scale bars indicate 15 µm and symbols mean significant differences: **p < 0.001; *p < 0.05
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Although the final performance of KPM335 materials 
in  vivo was excellent and indistinguishable from that of 
Origami B-derived nanoparticles, the larger nanoparticle 
size observed in the P1 fraction (Figs.  3a, 4), and par-
ticularly the higher cell penetrability of the P2 fraction 
in vitro were indicative of either a different conformation 
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Fig. 6 In vivo biodistribution of nanoparticles in tumor tissue. a Protein accumulation determined by ex vivo imaging of GFP‑emitted fluorescence 
by representative subcutaneous colorectal cancer tumors grown in mice (measurements performed 5 h after the intravenous administration of a 
500 μg nanoparticle dose). b Quantitation of GFP‑emitted fluorescence in tumors of the compared groups, expressed as total radiant efficiency 
(photon/s/cm2/sr/μW/cm2). c Representative micrographs of nanoparticle internalization, as detected by IHC with an anti‑GFP antibody, in the 
tumor cell cytosol and CXCR4 expression observed in tumor cells before nanoparticle injection in representative tumors. d Mean ± S.E. of CXCR4 
expression H‑score in tumor tissue (measured prior to nanoparticle administration) and GFP H‑score (a measure of nanoparticle internalization in 
tumor cells) of mice belonging to the Origami B, MC4100, KPM335, BW30270 or buffer‑treated groups. Note the similar level of CXCR4 expression in 
tumors among groups and the correlation between tumor‑emitted fluorescence and the amount of nanoparticle internalized in tumor cells
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of T22-GFP-H6 building blocks, a diversity in the archi-
tecture of nanoparticles produced in this particular 
strain, or both. Conformational protein variations were 
indeed identified by CD of P2 protein fractions (Fig. 8a), 
distinguishing KPM335- and BW30270-derived materi-
als as the extremes of a conformational spectrum. Since 
BW30270 is the endotoxin-containing, parental strain 
of the endotoxin-free KPM335 [13], the results suggest 
that genetic tailoring associated with LPS modification 
might have affected cell properties related to protein 
metabolism.
In a previous study [20], we have demonstrated that 
mutations in the E. coli genome that affect protein qual-
ity control activities (chaperones and proteases) impact 
on the architecture and function of produced pro-
tein nanoparticles [20]. Also, the growth of cultured 
KPM335 is slightly slower than that of the parental strain 
BW30270 [15]. Reduced bacterial growth, as promoted, 
for instance, by minimal defined media or by entering 
into the stationary phase, results in the modification of 
intracellular levels of chaperones such as increased levels 
of ClpB and IbpA and reduced levels of GrpE, HtpG and 
Hsc [26]. In this context, we wondered if the LPS engi-
neering of KPM335 might have resulted in a physiologi-
cal, indirect impact on protein processing by a modified 
cell factory through modification of chaperone balance. 
Transcriptomic analysis of main folding-assistant genes 
in KPM335 revealed significant differences regarding the 
parental BW30270 (Fig. 8b), and in some cases a pattern 
of expression that might be comparable to that found in 
proteomics of wild-type bacteria at the end of the expo-
nential growth phase (Fig. 8b). In particular, tig transcript 
levels are lower being the production of trigger factor 
associated with ribosomal protein expression and growth 
rate [26]. On the other hand, some heat shock protein 
genes are upregulated, in particular those involved in 
inclusion body disaggregation (clpB and ibpA) [27, 28] 
indicating enhanced aggregation in the endotoxin-free 
strain when comparing with the parental background. 
In this regard, the formation of inclusion bodies by 
an aggregation-prone protein is slightly favoured in 
KPM335 when compared to BW30270, as measured by 
the percentage of insoluble recombinant protein over the 
total protein yield (86.7 ± 1.2 versus 81.649 ± 1.4 %; data 
calculated from [15]). Also, ClpB and IbpA also respond, 
independently of protein production, to growth rate. 
They are present in higher amounts in stationary phase at 
least when cells are growing in complex medium and the 
growth rate declines gradually [26]. On the other hand, 
some heat shock protein genes are downregulated (e.g. 
grpE), that is again in agreement with the endotoxin-free 
strain growing slower, as there is a slight tendency that 
these heat shock proteins do not change with growth rate 
or they are present in lower amounts when the cells grow 
slower or approach stationary phase [26].
Conclusions
In summary, the set of seven different mutations in LPS 
biosynthesis genes of KPM335 promotes a reduction 
of the cell growth rate that impact, intrinsically, on the 
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Fig. 7 Nanoparticle biodistribution in normal tissues. a Representative ex vivo images of T22‑GFP‑H6 nanoparticles uptake in mouse brain, liver, 
kidney, lung or heart tissue after injection as measured by GFP‑emitted fluorescence. b Quantitation of GFP fluorescence expressed as radiant effi‑
ciency. Note the negligible level of detected fluorescence, being undistinguishable from the background fluorescence observed in vehicle‑treated 
mice. This was in contrast to the high level of nanoparticle accumulation observed in tumor tissues in the same animals (see Fig. 6)
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expression of several among the main chaperones of the 
E. coli quality control network. This may have indirect 
influences on the conformational status of recombinant 
aggregation-prone protein materials and their building 
blocks. Although a more complete systems level analy-
sis of KPM335 performance as a cell factory would be 
desirable, the set of data presented here indicates that 
LPS engineering secondarily affects the arm of the cells’ 
biosynthetic and maintenance machineries dealing with 
protein conformation. While this fact does not negatively 
affect the final quality (tumor-homing) and organization 
(self-assembling) of complex smart materials such as 
CXCR4-targeted protein nanoparticles, it indeed influ-
ences some of their relevant properties at the macro-
scopic level.
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Fig. 8 Conformational protein status and activity of the cell’s quality 
control. a Smoothed CD spectra from 250 to 205 nm of T22‑GFP‑H6 
produced by different E. coli strains and purified at higher imidazol 
concentration (P2). Beta sheet structure signal is detected at 218 nm. 
b Expression of chaperone genes in E. coli KPM335 compared to their 
expression levels in E. coli BW30270. Relative changes in expression of 
target genes as quantified by RT‑qPCR using the comparative 2−∆∆Ct 
method [25] and the ihfB gene for normalization were converted into 
log2 values to display the fold changes in log2 scale. The values repre‑
sent the means and standard deviations based on duplicate RT‑qPCR 
runs for each of the three independent biological replicates per strain. 
The statistical significance of the differential expression patterns was 
analyzed using the paired t test. *P < 0.05; **P < 0.01; ***P < 0.001; ns, 
not significant. Genes labelled with a dash are those whose expres‑
sion change (either up‑ or down‑regulation) is coincident with the 
proteomic analysis of a conventional E. coli strain when entering into 
the stationary phase (according to data from [26]). The tig, hscB, hchA 
and cbpA gene products were not monitored in this previous study
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